AtriCure shares dipped today despite fourth-quarter results that came in ahead of the consensus forecast. Shares of ATRC fell 2.8% at $33.25 apiece in mid-morning trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — rose 0.7%. The Mason, Ohio-based company posted losses of $9.8 million. That […]
AtriCure Inc.
AtriCure management expects Street-beating Q4 sales
AtriCure today announced preliminary fourth-quarter revenue results that beat the expectations of Wall Street analysts. The Mason, Ohio–based developer of surgical tools for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management expects to report Q4 2023 revenue of $106.5 million, up 21% year-over-year. The consensus on The Street was $102.43 million. […]
AtriCure adds J&J veteran to its board
AtriCure (Nasdaq:ATRC) announced today that it appointed longtime Johnson & Johnson executive Shlomi Nachman to its board of directors. Nachman most recently served as company group chair within the Johnson & Johnson Medical Devices (now MedTech) business. He also joined the board of transcatheter aortic valve replacement technology developer JenaValve in September. “I am thrilled […]
AtriCure stock rises on Street-beating Q1
AtriCure (Nasdaq:ATRC) shares are trending upward today on first-quarter results that beat the consensus forecast. Shares of ATRC ticked up 6.2% at $42.65 apiece in midday trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — rose 0.2%. The Mason, Ohio-based cardiovascular care company posted losses of […]
AtriCure treats first patient in stroke prevention trial
AtriCure (Nasdaq:ATRC) announced today that it treated the first patient in its left atrial appendage exclusion for stroke prevention (LeAAPS) trial. U.S. co-principal investigator Dr. Marc Gerdisch treated the first patient at Franciscan St. Francis Heart Center in Indianapolis. The prospective, randomized, blinded investigational device exemption (IDE) trial will evaluate the safety and effectiveness of […]
AtriCure beats The Street in Q3
AtriCure (Nasdaq:ATRC) shares were unchanged after hours today on third-quarter results that topped the consensus forecast. The Mason, Ohio-based cardiac ablation device company posted losses of $12.3 million. That amounts to 27¢ per share on sales of $83.2 million for the three months ended Sept. 30, 2022. AtriCure reported a massive bottom-line slide into the […]
AtriCure dips on mixed bag Q2
AtriCure (Nasdaq:ATRC) shares took a slight hit today on second-quarter results that were mixed compared to the consensus forecast. The Mason, Ohio-based cardiac ablation device company posted losses of $14.8 million, or 32¢ per share, on sales of $84.5 million for the three months ended June 30, 2022, for a slight bottom-line gain on sales […]
AtriCure treats first patient in Isolator Synergy clamp trial
AtriCure (Nasdaq:ATRC) announced today that it treated the first patient in its HEAL-IST clinical trial in Belgium. Dr. Mark LaMeir and Dr. Carlo de Asmundis treated the first patient in the HEAL-IST trial evaluating the AtriCure Isolator Synergy clamp for treating drug-refractory patients diagnosed with inappropriate sinus tachycardia (IST) at University Hospital Brussels. “Symptomatic IST […]
AtriCure launches clamp for cardiac tissue ablation
AtriCure (Nasdaq:ATRC) announced today that it launched the EnCompass Clamp as part of its Isolator Synergy ablation system. Mason, Ohio-based AtriCure received FDA 510(k) clearance for the EnCompass Clamp for the ablation of cardiac tissue during cardiac surgery to make concomitant surgical ablations more efficient. According to a news release, the platform includes parallel closure, […]
These medtech companies care a lot about research
They’re making glaucoma-treating stents, tumor-treating fields, coin-sized CGMs and more. Discover the medtech companies that spend the most on research as a percentage of revenue. The list comes from our annual Big 100 report, which examines the world’s 100 largest medical device companies and ranks them by revenue. (Check out our full Big 100 report […]
AtriCure beats The Street in Q2 results
AtriCure (NSDQ:ATRC) posted second-quarter results this week that beat the overall consensus on Wall Street. The Mason, Ohio-based company reported losses of -$16.3 million, or -36¢ per share, on sales of $71.4 million for the three months ended June 30 for a sales growth of 74.84% compared with Q2 2020. Adjusted to exclude one-time items, earnings […]